Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
Key facts
- Who runs it
- Peking Union Medical College Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 74 people, planned
- Started
- Sept 2026
- Expected to end
- Nov 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Prednisone
- tripterygium wilfordii
- Record updated
- 16 October 2026
Who can take part
- Age
- 45 years to 79 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age greater than 45 years and less than 80 years; women must be postmenopausal
- Diagnosis of IgG4-related disease meeting the 2020 Revised Comprehensive Diagnostic Criteria (Japan) or the 2019 ACR/EULAR classification criteria
- Active IgG4-RD, defined as an IgG4-RD Responder Index score of 2 or higher in at least one organ at enrollment
- Treatment-naive or relapsed after discontinuation of prior therapy
Who cannot take part
- Another autoimmune disease as the primary diagnosis
- Malignancy
- Active bacterial, fungal, viral, or mycobacterial infection
- Baseline liver-function abnormality (ALT greater than 2 times the upper limit of normal), renal insufficiency (CKD stage 3 or higher, GFR less than 60 mL/min), or heart failure
- Organ-threatening or otherwise unsuitable clinical phenotypes as judged by the investigator, including neurologic involvement and IgG4-related sclerosing cholangitis
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 45 and 79 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if tripterygium wilfordii added to prednisone can treat active IgG4-related disease (IgG4-RD) in adults 45 to 80 years of age. Women in the study must be postmenopausal. The main questions it aims to answer are:
Read full original descriptionShow less
* Does adding tripterygium wilfordii to prednisone lower the chance that IgG4-RD comes back at 12 months compared with prednisone alone? * Does the combination improve remission, disease activity scores, blood tests, quality of life, and remain acceptably safe? Researchers will compare prednisone alone to prednisone plus tripterygium glycoside tablets to see if the combination reduces relapse.
Participants will:
* Be assigned by chance to prednisone alone or prednisone plus tripterygium glycoside tablets 20 mg three times a day * Start prednisone at 0.6 to 0.8 mg/kg per day and taper it off within 6 months * Attend clinic visits at the start of the study and at 1, 3, 6, 9, and 12 months for exams, blood tests, disease scores, and imaging when needed * Report symptoms and any side effects during the 12-month follow-up
The 2 groups in the trial
- Prednisone MonotherapyExisting treatment, for comparison
Oral prednisone started at 0.6-0.8 mg/kg/day for 4 weeks, then tapered by 5 mg weekly to 15 mg/day, then by 1.25-2.5 mg weekly, and discontinued within 6 months.
Treatment: Prednisone
- Prednisone plus Tripterygium wilfordiiTreatment being tested
Oral prednisone started at 0.6-0.8 mg/kg/day for 4 weeks, then tapered by 5 mg weekly to 15 mg/day, then by 1.25-2.5 mg weekly, and discontinued within 6 months, plus tripterygium glycoside tablets 20 mg orally three times daily.
Treatment: Prednisone and tripterygium wilfordii
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Tripterygium Wilfordii for IgG4-Related Disease: A Randomized Controlled Trial
- Criteria questions
- Built from NCT07878585, who can take part
- Record updated
- 16 October 2026